Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Male and female patients with a diagnosis of type 2 diabetes mellitus and previously treated with not more than one drug~* Glycosylated haemoglobin A1 (HbA1c) 6.5 to 10.0% at Start of Run-in~Exclusion criteria:~* Myocardial infarction, stroke or transient ischemic attack TIA within 6 months prior to informed consent~* Impaired hepatic function~* Renal insufficiency with a creatinine clearance \< 50 mL/min~* Treatment with rosiglitazone, pioglitazone, glucagon like peptide 1 (GLP-1) analogues, insulin, dipeptidyl peptidase 4 (DPP-4) inhibitors or anti-obesity drugs 3 months prior to informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Patients received placebo matching 5mg linagliptin and placebo matching 100mg sitagliptin.
- Linagliptin (Type: EXPERIMENTAL): Patients received 5mg linagliptin, and placebo matching 100mg sitagliptin.
- Sitagliptin (Type: ACTIVE_COMPARATOR): Patients received 100mg sitagliptin, and placebo matching 5mg linagliptin.

Based on this trial design, predict the completion outcome and termination type (if applicable).